CELLPRO CEPRATE TUMOR DEPLETION PHASE III TRIAL
This article was originally published in The Gray Sheet
Executive Summary
CELLPRO CEPRATE TUMOR DEPLETION PHASE III TRIAL is expected to begin this month in patients with multiple melanoma, CEO Richard Murdoch told the New York Society of Security Analysts at an Oct. 25 meeting. The 125-patient, 15-center study is designed to look at the tumor purging effect of stem cells that have been processed through the device. The study is slated to begin as soon as FDA grants final approval for the trial; FDA conducted an initial review of the protocol and asked for modifications related to the study endpoints, which CellPro submitted in mid-October.